Inflammatory Bowel Disease Market to Reach USD 21 Billion in 2025, Driven by Next-Generation Therapies

Industry
โดย PR Newswire·Read original
Summary · why it matters

The inflammatory bowel disease market across the seven major markets was valued at USD 21 billion in 2025, with the United States accounting for the largest share. The total number of incident cases of inflammatory bowel disease in the seven major markets was around 181 million in 2025. Growth is being fueled by the rising prevalence of Crohn's disease and ulcerative colitis, increased adoption of advanced biologic therapies, and the emergence of novel mechanisms of action targeting IL-23, TL1A, and S1P pathways. Key pipeline candidates include Abivax's ABX464, Merck's Tulisokibart, RedHill Biopharma's RHB-204, and Teva Pharmaceuticals and Sanofi's duvakitug, among others. The anticipated launch of these next-generation therapies is expected to reshape the treatment landscape and address unmet needs in biologic-refractory patients.

Impact on stocks 10

Biotech & Genomic Medicine▲ · 6 stocks
Abivax SA
ABVX
▲ PositiveDemandrelevance

Abivax's ABX464 is named as a key pipeline candidate in the expanding IBD market.

Merck & Company Inc
MRK
▲ PositiveDemandrelevance

Merck's pipeline candidate Tulisokibart is mentioned as a key next-generation therapy for IBD, benefiting from growing market demand.

Health Care▲ · 3 stocks
Sanofi SA
SAN
▲ PositiveDemandrelevance

Sanofi's duvakitug (with Teva) is highlighted as a key pipeline candidate in a growing IBD market.

Critical Materials & Supply Chain▲ · 1 stocks

Theme Impact 1

Related news

▲

Bristol Myers Sotyktu Shows Two-Year PsA Efficacy in POETYK Study

Bristol Myers Squibb announced positive two-year results from the late-stage POETYK PsA-2 study of Sotyktu, or deucravacitinib, including its open-label extension. Among patients entering the extension, clinical responses improved from week 16 through week 52 and were sustained through week 104, with robust results across ACR20/50/70 and Minimal Disease Activity in both continuous Sotyktu patients and those who switched from placebo at week 16. The safety profile remained consistent through week 104 with no new safety signals; adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively. Sotyktu, an oral selective tyrosine kinase 2 inhibitor approved in the United States and numerous other countries for moderate-to-severe plaque psoriasis and active psoriatic arthritis, generated $156 million in first-half 2026 revenues, up 24% year over year. Data from the POETYK SLE-1 and SLE-2 studies in systemic lupus erythematosus are expected later in 2026, while Amgen's Otezla and Takeda's investigational zasocitinib, whose new drug application the FDA recently accepted for plaque psoriasis, remain competitive threats.
BMY ▲
Biotech & Genomic Medicine ▲
Zacks Investment Research·13hRead more →
3

Novo's Denecimig Wins CHMP Backing for Hemophilia A in EU

Novo Nordisk said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of denecimig, also known as Mim8, for the treatment of hemophilia A, with or without inhibitors, in adults and children. Denecimig is a next-generation factor VIIIa mimetic bispecific antibody given subcutaneously as routine prophylaxis, with flexible dosing that includes once-monthly, every-two-week and weekly administration, and it is being developed as a prefilled pen. Novo expects to launch the drug in the first European countries in the fourth quarter of 2026 under the brand name Frehemgo, followed by a broader rollout across the European Union beginning in early 2027. The positive opinion is supported by data from the FRONTIER clinical program, which comprises five studies evaluating denecimig as a prophylactic treatment for hemophilia A across pediatric and adult populations, with or without inhibitors; in the FRONTIER 2 study denecimig significantly reduced annualized bleeding rates, results in children younger than 12 in FRONTIER 3 were consistent with those in adolescents and adults, and in FRONTIER 5 no new safety concerns were identified when participants switched directly from emicizumab to denecimig. The candidate is also under regulatory review in the United States for routine prophylaxis in adults and children with hemophilia A, with or without inhibitors, after Novo submitted a biologics license application to the FDA in September 2025. Novo already markets Alhemo for hemophilia A and B in patients with or without inhibitors.
ACIUALDXNOV.XETRAPGEN
Biotech & Genomic Medicine ▲
Zacks Investment Research·16hRead more →
▼impact 4

Trump to Announce Most Favored Nation Drug Pricing for Medicaid in All 50 States

President Trump will announce on Friday that Medicaid beneficiaries in all 50 states will receive Most Favored Nation pricing discounts on some prescription drugs. The White House Council of Economic Advisers projects the move will generate $27.6B in savings for state governments and $36.6B for the federal government over 10 years, according to Semafor, which broke the news. Trump is also scheduled to meet today with the governors of Arkansas, Mississippi, and South Dakota to discuss progress on lowering drug prices. Separately, an AARP Public Policy Institute report released in August found that applying MFN pricing to the top 10 drugs by Medicare Part D and Part B spending in 2025 would cut Medicare spending on those drugs from $273B to $76B between 2029 and 2033.
ABBVJNJLLYMRKNOV.XETRAPFE+1
Biotech & Genomic Medicine ▼
Seeking Alpha·17hRead more →
© 2026 MarketDXNews